Detectnet Generic: When Will Generic Copper Cu-64 Dotatate Be Available?
This page is aggregated from FDA records, court filings and company announcements. Coded and designed by Dr. Brian Staiger, PharmD, BCPS
Updated October 9, 2026 How we build our data
Detectnet Generic at a Glance
Four quick answers from FDA records and our estimate.
- When is the first generic expected? September 2041 About 15 years away Why then?
- Has the FDA approved a generic? Not yet None in the FDA’s records yet Why not yet?
- When does the last patent end? September 2041 4 patents listed with the FDA
- Can you buy a generic today? Not yet No company lists one for sale
Generic copper cu-64 dotatate is expected to be available in September 2041, about 15 years away. None is for sale yet.
Why September 2041?
It is when Detectnet’s patent 12,102,696 ends. That patent covers the product’s formulation, and once it ends, generics can go on sale as soon as the FDA approves them. We rate it probable: more likely than not, but it can still move.
Why hasn’t the FDA approved a generic yet?
That is normal before a launch. The FDA usually can’t give a generic its final approval while a patent or exclusivity still blocks it, so final approval often comes close to the day the generic can be sold. No company holds a “tentative” approval yet either (the FDA’s word for a generic that is ready but still blocked).
Will the generic cost less?
Usually, but no company is recorded as having applied to make one yet, and a single company usually brings only a modest drop. See the price pattern
What should I do now?
Keep taking Detectnet as prescribed. When a generic arrives, your pharmacy may switch you to it automatically, and it may look different. What a generic means for you
Our month is only an estimate based on available information, so we never name a day.
Detectnet by the Numbers
- Reason
- Patent expiresA patent that protects the brand runs out. After that, approved generics can be sold.
- How sure
- Probable More likely than not, but it can still move.
- Price competition
- None filed yet No filers on record
- Brand sales
- Sales not reported
- FDA approved 2020 September 2020 FDA Orange Book
- Patents listed 4 last runs to September 2041 FDA Orange Book
- Medicaid prescriptions 12 in the last four reported quarters, $25.8K CMS Medicaid drug utilization, to Q1 2026
Detectnet’s Road to a Generic
Detectnet has had the market to itself since the FDA approved it in September 2020 (Curium US LLC). Its FDA protection (orphan drug) runs to September 2027. Its 4 listed patents run to September 2041.
The first generic of Detectnet is expected in September 2041.
Why that month: patent 12,102,696, on the product’s formulation, ends then.
Each bar runs from the brand’s approval to the day that protection ends. The green band is our projection for the first generic: a month, never a day, because legal dates move and a generic reaches shelves days to weeks after it is allowed. Sources: FDA Orange Book; the expected month from court records and company announcements.
Detectnet Patents and FDA Protections
Every patent and exclusivity the FDA Orange Book lists for Detectnet’s own applications. A protection running past the expected month does not mean the date is wrong: a settlement or a court ruling can let a generic in before a patent ends, and a patent on one formulation or use does not block every generic.
The one that matters for a generic launch: patent 12,102,696, which ends in September 2041, the month the first generic is expected.
| Patent | What it covers | Protects until | Status |
|---|---|---|---|
| 10,159,759 | A way of using it (U-2951) | August 2032 | Active |
| 11,160,888 | A way of using it (U-2951) | August 2032 | Active |
| 10,383,961 | A way of using it (U-2951) | July 2033 | Active |
| 12,102,696 Sets the expected month of generic availability | The product’s formulation | September 2041 | Active |
| Exclusivity | What it means | Ends | Status |
|---|---|---|---|
| Orphan drug ODE-317 | Seven years of protection for a use in a rare disease. | September 2027 | Active |
Source: FDA Orange Book, application 213227. Patent numbers open the patent on Google Patents.
Who Is Lined Up to Make Generic Copper Cu-64 Dotatate
Three steps stand between a brand and a generic you can buy: a company applies to the FDA, the FDA approves it, and the company starts selling it.
Applied to the FDA
No company is recorded as having applied to the FDA to make a generic Detectnet yet.
Approved by the FDA
Not yet. The FDA has not approved a generic copper cu-64 dotatate. Final approval often comes close to the day a generic can be sold.
For Sale in Pharmacies
Not yet. No company lists a generic copper cu-64 dotatate for sale with the FDA.
Sources: how many companies have applied, from court records and company announcements; approved generics from the FDA Orange Book; tentative approvals from Drugs@FDA; what is for sale from the FDA NDC Directory. The FDA does not disclose an application before it approves it (21 CFR 314.430).
Detectnet Price: What Pharmacies Pay and What Generics Usually Do
What a Generic Could Cost
How we estimate it. The national survey of what pharmacies pay (NADAC) has no recent price for Detectnet, so we cannot show dollars. Here is the FDA’s finding of how far the price pharmacies pay usually falls as generic companies join: about 31% with one company, 44% with two, 73% with four and over 95% with six or more (the typical drop for every drug whose first generic came out from 2015 to 2017).
Median prices pharmacies paid for the generic (invoice prices), compared with the brand’s price before generic entry, from FDA’s 2019 analysis “Generic Competition and Drug Prices”. At the manufacturer’s price FDA found steeper drops (about 39%, 54%, 79% and over 95%), the figures quoted elsewhere on this tracker. A typical pattern, not a price quote for this medicine.
What Medicare and Medicaid Spend on Detectnet
Big public spending is part of why generic makers line up for a medicine, and why its first generic matters beyond the pharmacy counter. Figures are before manufacturer rebates, which are confidential.
Medicaid Prescriptions by Quarter
12 prescriptions in the four quarters to Q1 2026, $25.8K paid.
See the numbers
| Quarter | Prescriptions | Medicaid paid |
|---|---|---|
| Q1 2026 | 12 | $25,816 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
Source: CMS Medicaid State Drug Utilization Data, over Detectnet’s own package codes.
Detectnet Strengths and Forms
| Strength | Form | How it is taken | Approved | Status |
|---|---|---|---|---|
| 4mL (1mCi/ML) | Solution | Intravenous | September 2020 | Prescription reference product |
Source: FDA Orange Book, Curium US LLC. Listed for sale today by Curium US LLC (FDA NDC Directory).
Detectnet NDC Codes and Packages
Each Detectnet package sold today has its own NDC, the product number printed on the box and on the pharmacy label. Open one to see that package’s details, what pharmacies pay for it and its patent timeline.
| NDC | Product | Package | Company |
|---|---|---|---|
| 69945-0064-01 | COPPER OXODOTREOTIDE CU-64 1 mCi/mL injection, solution | vial of 4 mL | Curium US LLC |
| 69945-0064-01 | COPPER OXODOTREOTIDE CU-64 1 mCi/mL injection, solution | vial of 4 mL | Curium US LLC |
Source: the FDA NDC Directory, current listings only. Only packages sold under Detectnet’s own FDA approval (NDA 213227) are listed, never a generic. Some codes belong to companies that repackage Detectnet: it is the same medicine in a different package.
What a Generic Detectnet Means for You
Nothing Changes Until It Is in Pharmacies
Until a generic is actually for sale, keep filling Detectnet as usual. When one arrives, there is nothing you need to sign up for.
Your Pharmacy May Switch You Automatically
Every state lets pharmacists fill a brand-name prescription with an FDA-approved generic rated as equivalent to it, and about 19 states require them to, unless your prescriber writes “dispense as written” or “brand medically necessary” on the prescription. Some states ask the pharmacist to tell you, or to get your OK first. A study of every state’s law has the details.
It Will Probably Look Different
US trademark law does not let a generic look exactly like the brand, so the color, shape or markings usually change. The active ingredient, strength and form are the same. An “authorized generic,” made by or for the brand’s own company, can look identical. The FDA explains.
Your Insurance May Change Too
Once a lower-cost version is available, many insurance plans charge more for the brand, or stop covering it. Your plan’s drug list (formulary) says how.
Until a generic is on US pharmacy shelves, be careful with websites that offer “generic Detectnet”. The FDA warns that unlicensed online pharmacies sell counterfeit and unapproved medicines; its BeSafeRx page shows how to check a pharmacy.
Questions people ask about Detectnet
Is there a generic for Detectnet right now?
No. As of October 9, 2026 no generic copper cu-64 dotatate is listed for sale in the FDA NDC Directory.
When will Detectnet go generic?
September 2041 is the expected month, and that is probable but not certain. It is when Detectnet’s patent 12,102,696 ends. That patent covers the product’s formulation, and once it ends, generics can go on sale as soon as the FDA approves them.
Will generic copper cu-64 dotatate be the same as Detectnet?
Yes in the ways that matter: the same active ingredient, strength and form, with proof that it reaches your blood the same way. Inactive ingredients can differ, which is why some people notice a different look or taste.
How much will the generic cost?
Nobody can say for sure before launch. No company is recorded as having applied to the FDA to make one yet, and a single company usually brings only a modest drop.
Has the FDA approved a generic Detectnet?
Not yet. The FDA Orange Book lists no approved generic version of Detectnet.
When does the Detectnet patent expire?
The FDA Orange Book lists 4 patents for Detectnet; the last runs to September 2041. The one behind the expected month is patent 12,102,696, which ends in September 2041. A patent date is not the launch date: settlements and court rulings often bring a generic earlier, and FDA approval or a company’s own plans can make it later. The expected month on this page (September 2041) weighs all of that.
Changes to This Projection
- First generic expected September 2041 on this month’s schedule. A line is added here whenever a monthly update moves the month, the reason or how sure it is.
Every change to the expected month is logged here with the month we saw it.
Also Going Generic
- BonjestaDoxylamine Succinate and Pyridoxine Hydrochloride2026 to 2027
- XywavCalcium Oxybate, Magnesium Oxybate, Potassium Oxybate, and Sodium OxybateDuring 2033
- PixclaraFloretyrosine F18September 2033
- FilsuvezBirch triterpenes2035 to 2036
- Tepadina and Sodium ChlorideThiotepaMay 2037
- LipfendraEnlicitide Decanoate2040 to 2041
About Detectnet
- Generic name copper cu-64 dotatate
- How it is taken Into a vein (IV)
- Company Curium US LLC
- Hard to copy Inhalers, injectables, patches and other hard-to-copy products. Fewer companies attempt them and dates slip more often.
- More drugs Brand-name drugs starting with D
- Have a question? A pharmacist answers, free. Ask about Detectnet
Sources. The expected month: FDA Paragraph IV Patent Certifications list, federal court records, company announcements and securities filings (settlement dates, launch plans, sales). The record on this page: FDA Orange Book, Drugs@FDA (tentative approvals), FDA NDC Directory, Medicaid State Drug Utilization Data, FDA, Generic Competition and Drug Prices (2019). Updated October 9, 2026. Information, not medical advice.